Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2006 Nov;5(11):2606-12.
doi: 10.1158/1535-7163.MCT-06-0433. Epub 2006 Nov 6.

Mutation analysis of 24 known cancer genes in the NCI-60 cell line set

Ogechi N Ikediobi  1 , Helen Davies, Graham Bignell, Sarah Edkins, Claire Stevens, Sarah O'Meara, Thomas Santarius, Tim Avis, Syd Barthorpe, Lisa Brackenbury, Gemma Buck, Adam Butler, Jody Clements, Jennifer Cole, Ed Dicks, Simon Forbes, Kristian Gray, Kelly Halliday, Rachel Harrison, Katy Hills, Jonathan Hinton, Chris Hunter, Andy Jenkinson, David Jones, Vivienne Kosmidou, Richard Lugg, Andrew Menzies, Tatiana Mironenko, Adrian Parker, Janet Perry, Keiran Raine, David Richardson, Rebecca Shepherd, Alex Small, Raffaella Smith, Helen Solomon, Philip Stephens, Jon Teague, Calli Tofts, Jennifer Varian, Tony Webb, Sofie West, Sara Widaa, Andy Yates, William Reinhold, John N Weinstein, Michael R Stratton, P Andrew Futreal, Richard Wooster
Affiliations

Mutation analysis of 24 known cancer genes in the NCI-60 cell line set

Ogechi N Ikediobi et al. Mol Cancer Ther. 2006 Nov.

Abstract

The panel of 60 human cancer cell lines (the NCI-60) assembled by the National Cancer Institute for anticancer drug discovery is a widely used resource. The NCI-60 has been characterized pharmacologically and at the molecular level more extensively than any other set of cell lines. However, no systematic mutation analysis of genes causally implicated in oncogenesis has been reported. This study reports the sequence analysis of 24 known cancer genes in the NCI-60 and an assessment of 4 of the 24 genes for homozygous deletions. One hundred thirty-seven oncogenic mutations were identified in 14 (APC, BRAF, CDKN2, CTNNB1, HRAS, KRAS, NRAS, SMAD4, PIK3CA, PTEN, RB1, STK11, TP53, and VHL) of the 24 genes. All lines have at least one mutation among the cancer genes examined, with most lines (73%) having more than one. Identification of those cancer genes mutated in the NCI-60, in combination with pharmacologic and molecular profiles of the cells, will allow for more informed interpretation of anticancer agent screening and will enhance the use of the NCI-60 cell lines for molecularly targeted screens.

PubMed Disclaimer

References

    1. Monks A, Scudiero D, Skehan P, et al. Feasibility of a high-flux anticancer drug screen usinga diverse panel of cultured human tumor cell lines. J Natl Cancer Inst. 1991;83:757–66. - PubMed
    1. Monks A, Scudiero D, Johnson G, Paull K, Sausville E. The NCI anticancer drug screen: a smart screen to identify effectors of novel targets. Anticancer Drug Des. 1997;12:533–41. - PubMed
    1. Holbeck SL. Update on NCI in vitro drug screen utilities. Eur J Cancer. 2004;40:785–93. - PubMed
    1. Paull K, Shoemaker R, Hodes L, et al. Display and analysis of patterns of differential activity of drugs against human tumor cell lines: development of mean graph and COMPARE algorithm. J Natl Cancer Inst. 1989;81:1088–92. - PubMed
    1. Weinstein JN, Kohn KW, Grever MR, et al. Neural computing in cancer drug development: predicting mechanism of action. Science. 1992;258:447–51. - PubMed

Publication types

Substances